about
Assessment of anti-inflammatory tumor treatment efficacy by longitudinal monitoring employing sonographic micro morphology in a preclinical mouse modelImpaired CK1 delta activity attenuates SV40-induced cellular transformation in vitro and mouse mammary carcinogenesis in vivoNuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells.Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathwaysTRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model.The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma.Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells.Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway.TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice.The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell.Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.CD95 and TRAF2 promote invasiveness of pancreatic cancer cells.Concerted deregulations of multiple apoptosis-controlling genes in pancreatic carcinoma cells.
P50
Q31020210-2A52A754-741C-41FC-88F1-67DA16354423Q34123850-1AB805F9-FCD3-4DEF-A181-18DF65CBC1BAQ35016268-53599A73-807E-421E-85BE-891738A22C3CQ35089228-F0464F38-AFD8-4BA5-9503-1660CDD4CF0DQ35173372-D58AFE6A-F0A8-4CF1-A976-679B19200093Q35832412-96686934-B091-4E7C-ACF1-C2EC01F88ACFQ37716512-EA4332C5-EBC5-460B-A78B-EE47D0F245D3Q37815648-E6DF8CB4-2D61-47DC-BBBC-DFF40E57230DQ38751590-EA0E41DB-96F0-45DE-BF32-ACF84EC9FFE0Q38902246-F89E3DF6-B34A-4B19-8064-AE0DA87307EFQ39197722-0C002249-0DF9-46DE-8D51-D283F92986F2Q39683156-99FFAB81-08BE-444A-B2AC-88A53DCF2380Q39720687-0F961DCF-5819-48D8-95A7-D819AE262136Q39989276-0B8785E6-2458-44CB-AB25-012424ECABB8Q39993928-FB1C1AE4-07BF-4BF2-83D8-1ABAAD09BC79Q40006251-42F08220-52EA-4917-8850-D97752A1622FQ40172656-820262D5-38BB-4852-8942-4A5CF96035A0Q40465691-CD13EE55-DF28-406C-B90D-32FD7B9F6D3EQ40576087-BB4CF778-662B-4712-8D0F-E4BFEDCFF81A
P50
description
onderzoeker
@nl
name
Anna Trauzold
@ast
Anna Trauzold
@en
Anna Trauzold
@es
type
label
Anna Trauzold
@ast
Anna Trauzold
@en
Anna Trauzold
@es
prefLabel
Anna Trauzold
@ast
Anna Trauzold
@en
Anna Trauzold
@es